Latest Articles and Analysis

Historical redlining policies correlate with current geographic disparities in HIV treatment access and care quality.

HHS budget proposal would eliminate critical HIV prevention funding and reduce Ryan White HIV/AIDS program resources.

Q2 2025 Watch monitoring HCV and HIV treatment access through ADAPs, Medicaid, and federal assistance.

Elimination of HIV data protections and surveillance capacity undermines disease tracking and outbreak response capability.

Trump administration's contradictory drug pricing policies undermine goals of affordability and innovation incentives.

Federal spending cuts disproportionately impact vulnerable populations relying on safety-net programs and community health services.

State Prescription Drug Affordability Boards limit public input while basing pricing decisions on flawed methodologies.

Deteriorating public health surveillance capacity creates blind spots for emerging disease threats and health disparities.

Long-acting injectable HIV treatments demonstrate clinical promise but face coverage and implementation barriers.

Copay accumulator programs exclude patient assistance from deductibles, creating barriers to medication adherence and treatment.

Declining vaccination rates and policy challenges create vulnerability to vaccine-preventable diseases and epidemic risk.

Convergence of influenza, avian flu, and tuberculosis threats reveals inadequate pandemic preparedness and disease response capacity.

Elimination of health equity research funding undermines evidence base for addressing healthcare disparities and structural inequalities.

Elimination of surveillance funding creates blind spots in disease tracking and health equity measurement.

Proposed Medicaid cuts and work requirements threaten coverage for millions including people living with HIV.

Q1 2025 Watch: comprehensive update on HIV/HCV co-infection treatment access across federal and state programs.

FTC investigation confirms pharmacy benefit managers extracted billions in excess revenue through specialty drug markup schemes.

DoxyPEP post-exposure prophylaxis demonstrates effectiveness for STI prevention with implementation challenges and equity concerns.

Insurance companies deploy AI algorithms for automated prior authorization denials, restricting patient access to prescribed treatments.

Pragmatic approach to healthcare policy reform requires accepting incremental progress while maintaining advocacy commitment.